Literature DB >> 17430364

The importance of impaired physical health and age in normal cognitive aging.

Ingvar Bergman1, Mari Blomberg, Ove Almkvist.   

Abstract

The objective of this study was to investigate the importance of impaired physical health and age in normal cognitive aging. In our cross-sectional, clinical and explorative study, medical and neuropsychological data from 118 voluntary healthy controls aged 26-91 years were collected from five recruitment occasions. Health was assessed according to a criterion reflecting clinical and subclinical severity. The examinations included a clinical investigation, brain neuroimaging, and a comprehensive neuropsychological assessment. Regression analyses showed a significant incidence of clinical and subclinical medical disorders that explained 10.8% of the variation in cognitive performance, while age-related impairment explained 5.6%. Findings of the central nervous system were important but various other medical findings explained about half of the health-related variation. Cognitively demanding tasks were more susceptible to impaired physical health while tasks comprising salient motor- and visual spatial elements were more prone to be impaired by age. Our findings suggest (1) that impaired physical health is more important than chronological age in accounting for cognitive impairment across the adult lifespan, (2) that age and health dissociate with regard to cognitive functions affected, and (3) that selection for so-called "super healthy" elderly people might be justified in cognitive research. Because the prevalent diseases in normal aging are potentially preventable, the present findings promise good prospect for prevention of future cognitive disability among elderly people.

Entities:  

Mesh:

Year:  2007        PMID: 17430364     DOI: 10.1111/j.1467-9450.2007.00594.x

Source DB:  PubMed          Journal:  Scand J Psychol        ISSN: 0036-5564


  12 in total

1.  II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus.

Authors:  Jason J Paris; Alicia A Walf; Cheryl A Frye
Journal:  Brain Res       Date:  2010-10-31       Impact factor: 3.252

2.  Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.

Authors:  I L Han Choo; Stephen F Carter; Michael L Schöll; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-31       Impact factor: 9.236

3.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Authors:  Ahmadul Kadir; Amelia Marutle; Daniel Gonzalez; Michael Schöll; Ove Almkvist; Malahat Mousavi; Tamanna Mustafiz; Taher Darreh-Shori; Inger Nennesmo; Agneta Nordberg
Journal:  Brain       Date:  2010-12-13       Impact factor: 13.501

4.  Selective impact of disease on short-term and long-term components of self-reported memory: a population-based HUNT study.

Authors:  Ove Almkvist; Ole Bosnes; Ingunn Bosnes; Eystein Stordal
Journal:  BMJ Open       Date:  2017-05-09       Impact factor: 2.692

5.  Examining age-related shared variance between face cognition, vision, and self-reported physical health: a test of the common cause hypothesis for social cognition.

Authors:  Sally Olderbak; Andrea Hildebrandt; Oliver Wilhelm
Journal:  Front Psychol       Date:  2015-08-12

6.  Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.

Authors:  Konstantinos Chiotis; Laure Saint-Aubert; Irina Savitcheva; Vesna Jelic; Pia Andersen; My Jonasson; Jonas Eriksson; Mark Lubberink; Ove Almkvist; Anders Wall; Gunnar Antoni; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236

7.  Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.

Authors:  Michael Schöll; Stephen F Carter; Eric Westman; Elena Rodriguez-Vieitez; Ove Almkvist; Steinunn Thordardottir; Anders Wall; Caroline Graff; Bengt Långström; Agneta Nordberg
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

8.  Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.

Authors:  Karra D Harrington; Yen Ying Lim; David Ames; Jason Hassenstab; Simon M Laws; Ralph N Martins; Stephanie Rainey-Smith; Joanne Robertson; Christopher C Rowe; Olivier Salvado; Vincent Doré; Victor L Villemagne; Peter J Snyder; Colin L Masters; Paul Maruff
Journal:  Alzheimers Dement (Amst)       Date:  2017-06-09

9.  Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.

Authors:  Steinunn Thordardottir; Elena Rodriguez-Vieitez; Ove Almkvist; Daniel Ferreira; Laure Saint-Aubert; Anne Kinhult-Ståhlbom; Håkan Thonberg; Michael Schöll; Eric Westman; Anders Wall; Maria Eriksdotter; Henrik Zetterberg; Kaj Blennow; Agneta Nordberg; Caroline Graff
Journal:  Alzheimers Res Ther       Date:  2018-05-10       Impact factor: 6.982

10.  Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain.

Authors:  Konstantinos Chiotis; Per Stenkrona; Ove Almkvist; Vladimir Stepanov; Daniel Ferreira; Ryosuke Arakawa; Akihiro Takano; Eric Westman; Andrea Varrone; Nobuyuki Okamura; Hitoshi Shimada; Makoto Higuchi; Christer Halldin; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.